Capricor Therapeutics (CAPR) Misses Q4 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Kaos Capital pushes for board changes at Capricor Therapeutics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance